Clinical evidence on the undertreatment of older and poor performance patients who have advanced non-small-cell lung cancer: Is there a role for targeted therapy in these cohorts?

Clinical Lung Cancer

Volumn 12, Issue 5, 2011, Pages 272-279

  Langer, Corey J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Advanced Non small cell lung cancer; Elderly; Erlotinib; Poor performance status; Targeted therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; VINORELBINE DITARTRATE;

ADVANCED CANCER; AGED; ANOREXIA; ANTIANGIOGENIC THERAPY; BLEEDING; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG UTILIZATION; FATIGUE; FEBRILE NEUTROPENIA; GERIATRIC PATIENT; GROUPS BY AGE; HEALTH CARE DISPARITY; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; SENSORY NEUROPATHY; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; SURVIVAL RATE;

EID: 80052428551     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.02.001     Document Type: Review

References (44)

1. K. Kelly, J. Crowley, and P.A. Bunn Jr Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced Non-small-cell lung cancer: a Southwest Oncology Group trial J Clin Oncol 19 2001 3210 3218 (Pubitemid 32591438)
2. J.H. Schiller, D. Harrington, and C.P. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98 (Pubitemid 34438899)
3. National Comprehensive Care Network NCCN Clinical Practice Guidelines in Oncology Non-small cell lung cancer. V.2.2010 http://www.nccn.org Accessed: June 22, 2010
4. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550 (Pubitemid 44917502)
5. R. Pirker, J.R. Pereira, and A. Szczesna Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised trial Lancet 373 2009 1525 1531
6. American Cancer Society Cancer Facts & Figures 2010 2010 American Cancer Society Atlanta
7. Surveillance Epidemiology and End Results (SEER) Program SEER Cancer Statistics Review 19752007 http://seer.cancer.gov Accessed: June 22, 2010
8. J. Vardy, R. Dadasovich, and P. Beale Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials BMC Cancer 9 2009 130 http://www.biomedcentral.com/1471-2407/9/130 Accessed June 22, 2010
9. R.A. Somer, E. Sherman, and C.J. Langer Restrictive eligibility limits access to newer therapies in Non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599 Clin Lung Cancer 9 2008 102 105 (Pubitemid 351631921)
10. R.C. Lilenbaum, J. Cashy, and T.A. Hensing Prevalence of poor performance status in lung cancer patients: implications for research J Thorac Oncol 3 2008 125 129 (Pubitemid 351323185)
11. D.F. Cella, and J.D. Patel Improving health-related quality of life in Non-small-cell lung cancer with current treatment options Clin Lung Cancer 9 4 2008 206 212
12. K. Lang, M.D. Marciniak, and D. Faries Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States Lung Cancer 63 2009 264 270
13. D. Hardy, C.C. Liu, and R. Xia Racial disparities and treatment trends in a large cohort of elderly black and white patients with Non-small cell lung cancer Cancer 115 2009 2199 2211
14. S.D. Ramsey, N. Howlader, and R.D. Etzioni Chemotherapy use, outcomes, and costs for older persons with advanced Non-small-cell lung cancer: evidence from Surveillance, Epidemiology and End Results-Medicare J Clin Oncol 22 2004 4971 4978 (Pubitemid 46638623)
15. C.C. Earle, P.J. Neumann, and R.D. Gelber Impact of referral patterns on the use of chemotherapy for lung cancer J Clin Oncol 20 2002 1786 1792 (Pubitemid 34273267)
16. F. Kassam, F.A. Shepherd, and M. Johnston Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer J Thorac Oncol 2 2007 39 43 (Pubitemid 47163927)
17. A.J. Davidoff, M. Tang, and B. Seal Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer J Clin Oncol 28 2010 2191 2197
18. A.L. Potosky, S. Saxman, and R.B. Wallace Population variations in the initial treatment of Non-small-cell lung cancer J Clin Oncol 22 2004 3261 3268 (Pubitemid 41103681)
19. E.A. Chrischilles, J.F. Pendergast, and K.L. Kahn Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer J Clin Oncol 28 2010 620 627
20. J.D. Hainsworth, L. Fang, and J.E. Huang BRIDGE: An open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer J Thorac Oncol 6 2011 109 114
21. M. Socinski, C.J. Langer, and J.E. Huang Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases J Clin Oncol 27 31 2009 5255 5261
22. F. Fossella, J.R. Pereira, and J. von Pawel Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced Non-small-cell lung cancer: the TAX 326 study group J Clin Oncol 21 2003 3016 3024 (Pubitemid 46606280)
23. C.J. Langer The "Lazarus Response" in treatment-naive, poor performance status patients with Non-small-cell lung cancer and epidermal growth factor receptor mutation J Clin Oncol 27 2009 1350 1354
24. E. Quoix, J. Oster, and V. Westeel Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC) J Clin Oncol 28 suppl 2010 18s abstr 2
25. C.P. Belani, S. Ramalingam, and M.C. Perry Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced Non-small-cell lung cancer J Clin Oncol 26 2008 468 473 (Pubitemid 351171701)
26. T. Sakakibara, A. Inoue, and S. Sugawara Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer Ann Oncol 21 4 2010 795 799
27. S.S. Ramalingam, S.E. Dahlberg, and C.J. Langer Outcomes for elderly, advanced-stage Non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group trial 4599 J Clin Oncol 26 2008 60 65
28. H.A. Wakelee, S.E. Dahlberg, and J.R. Brahmer Increased benefit from bevacizumab (BEV) in younger women with advanced NSCLC on Eastern Cooperate Oncology Group (ECOG) E4599 J Thor Oncol 3 suppl 4 2008 S282 abstract 131
29. N.B. Leighl, P. Zatloukal, and J. Mezger Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL) J Thorac Oncol 5 2010 1970 1976
30. M. Reck, J. von Pawel, and P. Zatloukal Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAiL J Clin Oncol 27 2009 1227 1234
31. Tarceva (erlotinib) tablets [prescribing information] 2010 OSI Pharmaceuticals Inc Melville, NY South San Francisco, CA Genentech
32. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 951
33. R. Rosell, T. Moran, and C. Queralt Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 10 2009 958 967
34. M. Maemondo, A. Inoue, and K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 25 2010 2380 2388
35. C. Zhou, Y.L. Wu, and G. Chen Efficacy results from the randomized phase III OPTIMA (CTON 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer patients (pts) with EGFR activating mutations Ann Oncol 21 suppl 8 2010 viii6 abstract LBA13
36. D.M. Jackman, B.Y. Yeap, and N.I. Lindeman Phase II clinical trial of chemotherapy-naive patients <70 years of age treated with erlotinib for advanced Non-small-cell lung cancer J Clin Oncol 25 2007 760 766 (Pubitemid 350002874)
37. T. Stinchcombe, D.S. Bradford, and C.B. Lee Preliminary results of a randomized phase II trial of first-line treatment of gemcitabine (G) versus erlotinib (E) versus gemcitabine and erlotinib (GE) in patients 70 years or older with advanced non-small cell lung cancer (NSCLC) J Clin Oncol 28 7s 2010 abstract 7576 and poster presented at the Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010
38. M. Reck, J. Von Pawel, and J.R Fischer Erlotinib versus carboplatin/vinorelbine in elderly patients (age 70 or older) with advanced non-small cell lung carcinoma (NSCLC): a randomized phase II study of the German Thoracic Oncology Working Group J Clin Oncol 28 7s 2010 abstract 7565
39. H. Le Caer, F. Barlesi, and R. Corre A multicenter phase II randomized study of docetaxel (D)/gemcitabine (G) weekly followed by erlotinib (E) after progression versus erlotinib followed by docetaxel/gemcitabine after progression in advanced non-small cell lung cancer (NSCLC) in fit elderly patients selected with a comprehensive geriatric assessment (CGA): Groupe Franais de Pneumocancerologie (GFPC) (*)0504 J Clin Oncol 28 7s 2010 abstract 7536
40. C. Gridelli, F. Ciardiello, and R. Feld International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial J Clin Oncol 28 suppl 2010 15s abstr 7508
41. L. Crin, F. Cappuzzo, and P. Zatloukal Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study J Clin Oncol 26 26 2008 4253 4260
42. R.C. Lilenbaum, R. Axelrod, and S. Thomas Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced Non-small-cell lung cancer and a performance status of 2 J Clin Oncol 26 2008 863 869 (Pubitemid 351398077)
43. A. Inoue, K. Kobayashi, and K. Usui First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy J Clin Oncol 27 2009 1394 1400
44. S. Lee, R. Rudd, and I. Hkan TOPICAL: randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy J Clin Oncol 28 suppl 2010 15s abstr 7504